nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Air pollution and asthma incidence: doubt no more?
|
Georas, Steve N |
|
2015 |
3 |
12 |
p. 902-903 2 p. |
artikel |
2 |
ARDS in 2015: new clinical directions, new biological insights
|
Calfee, Carolyn S |
|
2015 |
3 |
12 |
p. 912-913 2 p. |
artikel |
3 |
Asthma: a focus on four key areas in 2015
|
Weiss, Scott T |
|
2015 |
3 |
12 |
p. 913-915 3 p. |
artikel |
4 |
AstraZeneca halts two lung cancer drug trials
|
Gourd, Katherine |
|
2015 |
3 |
12 |
p. 926- 1 p. |
artikel |
5 |
Bronchiectasis: working together for better evidence
|
Chalmers, James D |
|
2015 |
3 |
12 |
p. 915-917 3 p. |
artikel |
6 |
Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis
|
Kendall, Emily A |
|
2015 |
3 |
12 |
p. 963-972 10 p. |
artikel |
7 |
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true?
|
Odeyale, Foluke |
|
2015 |
3 |
12 |
p. e38- 1 p. |
artikel |
8 |
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true?
|
Nielen, Johannes T H |
|
2015 |
3 |
12 |
p. e38-e39 nvt p. |
artikel |
9 |
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true?
|
Davies, Neil M |
|
2015 |
3 |
12 |
p. e39-e40 nvt p. |
artikel |
10 |
Cardiovascular and neuropsychiatric risks of varenicline: too good to be true? – Authors' reply
|
Kotz, Daniel |
|
2015 |
3 |
12 |
p. e40-e42 nvt p. |
artikel |
11 |
Changing minds about tuberculosis
|
The Lancet Respiratory Medicine, |
|
2015 |
3 |
12 |
p. 901- 1 p. |
artikel |
12 |
CHEST Annual meeting 2015
|
Burki, Talha Khan |
|
2015 |
3 |
12 |
p. 925- 1 p. |
artikel |
13 |
Childhood asthma prediction models: a systematic review
|
Smit, Henriette A |
|
2015 |
3 |
12 |
p. 973-984 12 p. |
artikel |
14 |
Corrections
|
|
|
2015 |
3 |
12 |
p. e44- 1 p. |
artikel |
15 |
Corrections
|
|
|
2015 |
3 |
12 |
p. e44- 1 p. |
artikel |
16 |
Corrections
|
|
|
2015 |
3 |
12 |
p. e44- 1 p. |
artikel |
17 |
Exposure to air pollution and development of asthma and rhinoconjunctivitis throughout childhood and adolescence: a population-based birth cohort study
|
Gehring, Ulrike |
|
2015 |
3 |
12 |
p. 933-942 10 p. |
artikel |
18 |
First-in-human trial of a live-attenuated Mycobacterium tuberculosis vaccine
|
Geldmacher, Christof |
|
2015 |
3 |
12 |
p. 906-907 2 p. |
artikel |
19 |
Getting the story
|
Jones, Barbara |
|
2015 |
3 |
12 |
p. 932- 1 p. |
artikel |
20 |
Hyperinflation in COPD exacerbations
|
van Geffen, Wouter H |
|
2015 |
3 |
12 |
p. e43-e44 nvt p. |
artikel |
21 |
Idiopathic pulmonary fibrosis: continuing to make progress
|
Lee, Joyce S |
|
2015 |
3 |
12 |
p. 921-923 3 p. |
artikel |
22 |
Immunotherapy: the third wave in lung cancer treatment
|
Heigener, David Felix |
|
2015 |
3 |
12 |
p. 923-924 2 p. |
artikel |
23 |
Inhaled budesonide in bronchopulmonary dysplasia
|
Yaqub, Farhat |
|
2015 |
3 |
12 |
p. 926- 1 p. |
artikel |
24 |
International donor conversion rates for lung transplantation need to be standardised
|
Riddell, Peter |
|
2015 |
3 |
12 |
p. 909-911 3 p. |
artikel |
25 |
Jonas Salk
|
Akkermans, Rebecca |
|
2015 |
3 |
12 |
p. 930-931 2 p. |
artikel |
26 |
Lessons for pulmonary critical care from treatment of Ebola virus disease in developed countries
|
Bhadelia, Nahid |
|
2015 |
3 |
12 |
p. 919-921 3 p. |
artikel |
27 |
Lung health care—what does the future have in store?
|
Thorley, Jennifer |
|
2015 |
3 |
12 |
p. 927- 1 p. |
artikel |
28 |
MDR tuberculosis control: time to change the dogma?
|
Van Rie, Annelies |
|
2015 |
3 |
12 |
p. 907-909 3 p. |
artikel |
29 |
Nutritional support and refeeding syndrome in critical illness
|
van Zanten, Arthur Raymond Hubert |
|
2015 |
3 |
12 |
p. 904-905 2 p. |
artikel |
30 |
Restricted versus continued standard caloric intake during the management of refeeding syndrome in critically ill adults: a randomised, parallel-group, multicentre, single-blind controlled trial
|
Doig, Gordon S |
|
2015 |
3 |
12 |
p. 943-952 10 p. |
artikel |
31 |
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial
|
Spertini, François |
|
2015 |
3 |
12 |
p. 953-962 10 p. |
artikel |
32 |
SUPPORT controversy's lessons for informed consent
|
Furlow, Bryant |
|
2015 |
3 |
12 |
p. 928-929 2 p. |
artikel |
33 |
The complex challenge of chronic obstructive pulmonary disease
|
Duffy, Sean |
|
2015 |
3 |
12 |
p. 917-919 3 p. |
artikel |
34 |
Use of FEV1 as a measure of lung health in the UK BiLEVE study
|
Warner, David O |
|
2015 |
3 |
12 |
p. e42- 1 p. |
artikel |
35 |
Use of FEV1 as a measure of lung health in the UK BiLEVE study – Authors' reply
|
Wain, Louise V |
|
2015 |
3 |
12 |
p. e42-e43 nvt p. |
artikel |